Bonavis Injection (Ibandronate Sodium Monohydrate)
Ibandronate Sodium Monohydrate 3.375mg
Injections · Prescription medication
Palmgen Science Co., Ltd.
MFDS item code 201800259 · Notified 2018.01.18 · Insurance code 670104201
Treatment of osteoporosis in postmenopausal women
This medication is used for the treatment of osteoporosis, which often occurs in women following menopause. Osteoporosis is a condition where bones become weak and the risk of fractures increases. This medication helps to increase bone strength and improve bone density. By doing this, it reduces the risk of fractures and helps maintain a healthy bone condition.
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. Administration of this medicine is not recommended for patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, as clinical experience is insufficient. Elderly No dose adjustment is necessary.
Efficacy and safety in children 18 years of age or younger have not been studied.
This medication must only be administered via intravenous injection, and extreme caution must be taken if improperly administered near arteries or veins to avoid tissue damage. This medication should not be used in patients with a known allergy to it or its ingredients, or in patients with untreated hypocalcemia. Possible side effects during treatment include gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, etc., many of which are mild to moderate and often do not require discontinuation of treatment. Muscle pain, joint pain, headaches, rashes, fatigue, flu-like symptoms have also been reported, and flu-like symptoms may particularly occur during the initial phase of injection. Rarely, long-term use of this medication may result in osteonecrosis of the jaw; hence, it is important to conduct dental screening prior to administration and to avoid excessive dental treatment during therapy. If there is ear pain or discharge, the possibility of osteonecrosis of the external auditory canal should be considered. This medication may cause bone, joint, and muscle pain, and if pain is severe after administration, it is essential to consult with healthcare professionals. Atypical fractures may occur in the femur and other bones, so prompt evaluation should occur if there is pain in the thigh or groin. Pregnant or nursing women are advised not to use this medication due to lack of confirmed safety. This medication may affect kidney function, thus regular check-ups are necessary for patients with renal disease or those taking medications affecting the kidneys. In case of overdose, hypocalcemia, hypophosphatemia, etc., may occur, requiring rapid treatment and monitoring; dialysis may not be effective. This medication should not be mixed with a calcium-containing solution and must only be given as an intravenous injection. Used injection needles and syringes should not be reused and should be disposed of safely.
Gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, musculoskeletal pain, joint pain, myalgia, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reactions, phlebitis, thrombophlebitis, hypersensitivity reactions, angioedema, facial swelling, edema, urticaria, osteonecrosis of the jaw and external auditory canal, uveitis, epibulbar inflammatory disease, scleritis, anaphylactic reaction, shock, exacerbation of asthma, allergic reaction, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical femoral fracture, subtrochanteric femoral fracture, dizziness, optic neuropathy, lower motor neuron disease, tremor, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular bleeding, heart failure, urinary disorders, hematuria, skin desquamation, sensory loss, acute renal failure
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent exposure to air or moisture, ideally at room temperature between 1 and 30 degrees Celsius. Such storage helps to maintain the effectiveness of the medication.
It is an injection in a colorless and transparent solution contained in a colorless and transparent glass prefilled syringe with a single-use injection needle attached.
3ml x 1 vial
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ibandronate Sodium Monohydrate 3.375mg
Injections · Prescription medication
Palmgen Science Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.